The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score–Matched Study
Nirmatrelvir-ritonavir was associated with decreased risk of hospitalization within 30 days and 1-year risk of MACE and death in patients with CKD and kidney failure.
Authors
- Sophia Zhao (ORCID: https://orcid.org/0009-0008-6914-3583)
- Sherley M. Mejia (ORCID: https://orcid.org/0009-0000-3563-1521)
- Tianqi Ouyang (ORCID: https://orcid.org/0000-0001-5949-0911)
- Roby P. Bhattacharyya (ORCID: https://orcid.org/0000-0001-6955-5088)
- Destiny Harden (ORCID: https://orcid.org/0000-0003-3463-5429)
- Meghan E. Sise (ORCID: https://orcid.org/0000-0002-4327-9713)
- Meghan Lee (ORCID: https://orcid.org/0000-0002-6895-5968)
- Ian A. Strohbehn (ORCID: https://orcid.org/0000-0003-2167-2896)
- Andrew Cao
Institutions
- Massachusetts General Hospital (US)
- Brookline Public Schools (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1093/ofid/ofae756
- Citations
- 3
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Massachusetts General Hospital
- Gilead Sciences
- Angion
- National Institutes of Health